Barry W. Weiner, the President, CFO and Director of Enzo Biochem, Inc. (ENZ), Interviews with The Wall Street Transcript

Wall Street Transcript

67 WALL STREET, New York - August 16, 2013 - The Wall Street Transcript has just published its Medical Research, Diagnostic Substances and Life Science Tools Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care Consolidation Activity - Cost Reduction and Improving Efficiencies - Cost Reduction Amid Reimbursement Uncertainty - Health Care Growth Sectors Identified

Companies include: Enzo Biochem Inc. (ENZ) and many more.

In the following excerpt from the Medical Research, Diagnostic Substances and Life Science Tools Report, the President, CFO and Director of Enzo Biochem, Inc. (ENZ) discusses company strategy and the outlook for this vital industry:

TWST: Tell us about Enzo's competitive advantages. Are there other companies taking a similar approach as Enzo?

Mr. Weiner: One of our key competitive advantages is that we have a bifurcated marketing capability. Enzo Life Sciences is a company with a very strong global marketing channel, including on-the-ground operations throughout the United States and Europe, as well as agreements with 40 or so non-U.S. distributors and a highly effective electronic platform. This provides us with strong penetration and reach, which means we can take a product and provide it as a kit to our customer base of clinical labs, academic researchers and pharma, and at the same time utilize these internally validated products in services we provide through our clinical laboratory.

The lab is an important asset in this regard, because it provides us with the capabilities of sample collection for clinical validation and clinical trial. It also provides us with a base of distribution for new forms of diagnostic tests through our own clientele numbering between 2,000 and 4,000 physicians in our region. We have a significant presence in what is considered to be one of the most highly valued clinical diagnostic markets in the United States and its wide base of opinion leaders.

On the product front, we see the AmpiProbe platform as a low-cost option to current DNA, RNA amplification technologies. It will provide the ability to determine multiple disease indications from a single sample, a capability which will become important in the emerging era of tightened medical reimbursement. This is not to be confused with multiplexing, which is taking specimens and processing them from one sample through different channels. This is the ability to be able to actually analyze multiple analytes from a single specimen. The value of this is, number one, cost, because you are able to eliminate much of the upfront sample collection and preparation expenses connected with multiple specimens. And second, is that it can...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)